Paul C.
08-22-2003, 08:44 AM
Generex Biotechnology announces $224 000 Phase I National Institute of Health Small Business Innovative Research (SBIR) Award for Preclinical Development of a Novel HER-2/neu Peptide Vaccine for Breast Cancer. This novel vaccine stimulates the immune system to segments of HER-2/neu a dominant antigen found on certain breast cancer cells.